Free Trial
NASDAQ:NVCT

Nuvectis Pharma Q2 2025 Earnings Report

Nuvectis Pharma logo
$6.00 -0.17 (-2.76%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$6.00 0.00 (-0.08%)
As of 08/8/2025 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvectis Pharma EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.25
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Nuvectis Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nuvectis Pharma Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
9:00AM ET

Nuvectis Pharma Earnings Headlines

Roth Capital Cuts Earnings Estimates for Nuvectis Pharma
Nuvectis (NVCT) Q2 Loss Widens 43%
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
Roth Capital Reduces Earnings Estimates for Nuvectis Pharma
See More Nuvectis Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvectis Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvectis Pharma and other key companies, straight to your email.

About Nuvectis Pharma

Nuvectis Pharma (NASDAQ:NVCT), a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

View Nuvectis Pharma Profile

More Earnings Resources from MarketBeat